Trial Profile
A Phase II, Open Label, Uncontrolled and Multicenter Trial of Pazopanib Given as a Single Agent in Patients With Progressive Advanced/Metastatic Neuroendocrine Tumors (NET): a Search for Activity, Safety, and Predictive Biomarkers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Carcinoid tumour; Gastrointestinal cancer; Lung cancer; Malignant thymoma; Neuroendocrine tumours; Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- Acronyms PAZONET
- 23 Apr 2023 Results pooled analysis from SU11248, SUN1111), Pazopanib (PAZONET), sorafenib-bevacizumab (GETNE0801) and Lenvatinib (TALENT) published in the European Journal of Cancer
- 17 Aug 2016 Status changed from active, no longer recruiting to completed.
- 29 Sep 2015 Interim data expected by the end of 2015, as per Oxigene media release.